NVN Liquidation Inc (NOVNQ)
0.00
0.00 (0.00%)
USD |
OTCM |
Apr 30, 16:00
NVN Liquidation SG&A Expense (Quarterly): 10.04M for March 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2023 | 10.04M |
December 31, 2022 | 6.952M |
September 30, 2022 | 8.562M |
June 30, 2022 | 8.594M |
March 31, 2022 | 9.994M |
December 31, 2021 | 4.257M |
September 30, 2021 | 2.969M |
June 30, 2021 | 2.431M |
March 31, 2021 | 2.686M |
December 31, 2020 | 2.424M |
September 30, 2020 | 3.108M |
June 30, 2020 | 3.232M |
March 31, 2020 | 2.507M |
December 31, 2019 | 1.817M |
September 30, 2019 | 2.29M |
June 30, 2019 | 3.311M |
Date | Value |
---|---|
March 31, 2019 | 2.994M |
December 31, 2018 | 2.712M |
September 30, 2018 | 3.295M |
June 30, 2018 | 2.62M |
March 31, 2018 | 2.88M |
December 31, 2017 | 2.459M |
September 30, 2017 | 2.762M |
June 30, 2017 | 3.361M |
March 31, 2017 | 4.531M |
December 31, 2016 | 4.01M |
September 30, 2016 | 2.493M |
June 30, 2016 | 3.467M |
March 31, 2016 | 3.367M |
December 31, 2015 | 3.407M |
September 30, 2015 | 2.449M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.817M
Minimum
Dec 2019
10.04M
Maximum
Mar 2023
4.698M
Average
3.17M
Median
SG&A Expense (Quarterly) Benchmarks
NovaBay Pharmaceuticals Inc | 2.609M |
Palatin Technologies Inc | 3.033M |
iBio Inc | 2.961M |
Theriva Biologics Inc | 2.021M |
Oragenics Inc | 1.754M |